You forgot one important factor
stockmonster6 wrote:My observation is this:

SONA has had "it's day" in the spotlight, with less information and less progress which shot it to $16.  People, including SONA investors are more cautious now.

Therambright is ahead of SONA wrt to the Salvia test.

The potential is, if we max out expectations:

SONA - $2 to $16 (8 times)  Shares outstanding ~ 52.2 million.. Market cap = ~$ 98.2 million
THRM - $.50 to $16 (32 times) Shares outstanding ~210.47 million.. Market cap = ~$92.6 million
Now get your calculator back out Einstein.. LOL.. as you've just exposed your level of investment prowess again.. LOL..

With THRM's share price being less than SONA, the potential when FDA and HC news breaks (for either/or, and assuming they have competitive tests) is higher for THRMA.

Given SONA's past issues, and putting the cart before the horse (and the various class actions suits it seems), THRM is a better bet in the short term.  I believe SONA is once again going the wrong direction with seeking approvals before any lab tests have been publicized.

Just my take.  I'm already heavily invested in THRM.  If I had owned any SONA, at this point, the ability to make more $$ and for many, to recover losses, remains higher in THRM.